Difference between revisions of "Eltrombopag (Promacta)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 15: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 11/20/2008: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129214.htm Initial | + | * 11/20/2008: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129214.htm Initial approval] for treatment of thrombocytopenia in patients with [[Immune_thrombocytopenia | chronic immune (idiopathic) thrombocytopenia (ITP)]] who have had an insufficient response to [[:Category:Steroids|corticosteroids]], immunoglobulins, or splenectomy. |
| − | * 11/19/2012: | + | * 11/19/2012: Approved for treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. ''(Non-hematologic indication)'' |
| − | * 8/26/2014: | + | * 8/26/2014: Approved for patients with [[Aplastic anemia | severe aplastic anemia]] who have had an insufficient response to immunosuppressive therapy. |
| − | * 8/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm459467.htm | + | * 8/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm459467.htm Approved] for the treatment of thrombocytopenia in pediatric patients 1 year and older with [[Immune_thrombocytopenia |chronic immune (idiopathic) thrombocytopenia (ITP)]] who have had an insufficient response to [[:Category:Steroids|corticosteroids]], immunoglobulins, or splenectomy. |
| − | + | ==History of changes in EMA indication== | |
| + | *3/11/2010: Initial authorization as Revolade | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' SB-497115-GR | *'''Code name:''' SB-497115-GR | ||
| Line 36: | Line 37: | ||
[[Category:FDA approved in 2008]] | [[Category:FDA approved in 2008]] | ||
| + | [[Category:EMA approved in 2010]] | ||
Revision as of 13:36, 31 December 2022
General information
Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Eltrombopag (Promacta) package insert[1]
- Eltrombopag (Promacta) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/20/2008: Initial approval for treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
- 11/19/2012: Approved for treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. (Non-hematologic indication)
- 8/26/2014: Approved for patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
- 8/24/2015: Approved for the treatment of thrombocytopenia in pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
History of changes in EMA indication
- 3/11/2010: Initial authorization as Revolade
Also known as
- Code name: SB-497115-GR
- Brand names: Eltrom, Promacta, Revolade